BCAXBicara Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Bicara Therapeutics Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAXThis | $1.5B#8 | — | 3.1x#4 | — | — | -102.9%#11 | — | -29.4%#7 | — | — | 95.6%#5 | — |
| KARD | $1.6B#1 | — | 2.6x#2 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ETON | $1.6B#2 | — | 34.6x#11 | 20.1x#7 | 104.9%#3 | -20.4%#9 | -1.1%#5 | -9.9%#6 | -1.8%#4 | 4#3 | 220.3%#1 | — |
| ANAB | $1.6B#3 | — | 124.0x#14 | 6.7x#5 | 157.0%#2 | 90.9%#3 | 20.4%#2 | -103.8%#13 | — | — | 180.0%#2 | — |
| SNDX | $1.5B#4 | — | 102.1x#13 | 8.9x#6 | 627.8%#1 | 10.5%#6 | -158.4%#7 | -1890.2%#14 | -1205.8%#6 | — | 14.9%#8 | — |
| AVLN | $1.5B#5 | — | 3.9x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| INVA | $1.5B#6 | 4.9x#3 | 1.2x#1 | 3.7x#2 | 14.7%#7 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#2 | 9.8%#9 | — |
| DMRA | $1.5B#7 | 3.2x#2 | 2.9x#3 | — | — | -878.8%#13 | — | -40.7%#11 | — | — | — | — |
| TYRA | $1.5B#9 | — | 4.1x#8 | — | — | -38.7%#10 | — | -33.9%#9 | — | — | 96.4%#4 | — |
| XERS | $1.4B#10 | — | — | 4.9x#4 | 43.7%#4 | 101.0%#2 | 8.5%#4 | — | 20.6%#1 | — | 4.4%#10 | — |
| TRAX | $1.4B#11 | — | 8.3x#10 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LBRX | $1.4B#12 | 1.9x#1 | 4.1x#9 | — | — | 60.1%#5 | — | -7.6%#5 | — | — | 170.5%#3 | — |
| AVBP | $1.4B#13 | — | 3.7x#6 | — | — | -106.6%#12 | — | -45.3%#12 | — | — | 52.3%#6 | — |
| ORIC | $1.3B#14 | — | 3.4x#5 | — | — | -1.3%#8 | — | -34.0%#10 | -40.4%#5 | — | 15.1%#7 | — |
| HROW | $1.3B#15 | — | 84.4x#12 | 4.7x#3 | 36.4%#5 | 70.6%#4 | 11.2%#3 | -33.8%#8 | 13.2%#3 | 6#1 | -20.2%#11 | — |
| RARE | $1.3B#16 | — | — | 1.9x#1 | 20.2%#6 | -1.1%#7 | -79.5%#6 | — | — | — | -56.3%#12 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice